Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.490
+0.060 (4.20%)
At close: Mar 4, 2026, 4:00 PM EST
1.510
+0.020 (1.34%)
Pre-market: Mar 5, 2026, 7:38 AM EST
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 6.75, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 353.02% from the current stock price of 1.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 19, 2025.
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +235.57% | Dec 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +369.80% | Dec 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +436.91% | Nov 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +369.80% | Nov 4, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +235.57% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
2.87M
from 16.15M
Decreased by -82.24%
Revenue Next Year
n/a
from 2.87M
EPS This Year
-1.36
from -1.32
EPS Next Year
-1.23
from -1.36
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.0M | n/a | ||||
| Avg | 2.9M | n/a | ||||
| Low | 2.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -81.7% | - | ||||
| Avg | -82.2% | - | ||||
| Low | -83.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.32 | -0.83 | ||||
| Avg | -1.36 | -1.23 | ||||
| Low | -1.35 | -1.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.